220 related articles for article (PubMed ID: 11389706)
1. Allogeneic bone marrow transplantation for chronic myeloid leukemia: a retrospective study of busulfan-cytoxan versus total body irradiation-cytoxan as preparative regimen in Koreans.
Kim I; Park S; Kim BK; Chang HM; Bang SM; Byun JH; Kim DJ; Min WS; Kim HJ; Kim CC
Clin Transplant; 2001 Jun; 15(3):167-72. PubMed ID: 11389706
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM).
Devergie A; Blaise D; Attal M; Tigaud JD; Jouet JP; Vernant JP; Bordigoni P; Ifrah N; Dauriac C; Cahn JY
Blood; 1995 Apr; 85(8):2263-8. PubMed ID: 7718899
[TBL] [Abstract][Full Text] [Related]
3. Improved survival after bone marrow transplantation for early leukemia using busulfan-cyclophosphamide and individualized prophylaxis against graft-versus-host disease: a long-term follow-up.
Aschan J; Carlens S; Hägglund H; Klaesson S; Mattsson J; Remberger M
Clin Transplant; 1999 Dec; 13(6):512-9. PubMed ID: 10617242
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.
Nagler A; Rocha V; Labopin M; Unal A; Ben Othman T; Campos A; Volin L; Poire X; Aljurf M; Masszi T; Socie G; Sengelov H; Michallet M; Passweg J; Veelken H; Yakoub-Agha I; Shimoni A; Mohty M
J Clin Oncol; 2013 Oct; 31(28):3549-56. PubMed ID: 23980086
[TBL] [Abstract][Full Text] [Related]
5. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies.
Socié G; Clift RA; Blaise D; Devergie A; Ringden O; Martin PJ; Remberger M; Deeg HJ; Ruutu T; Michallet M; Sullivan KM; Chevret S
Blood; 2001 Dec; 98(13):3569-74. PubMed ID: 11739158
[TBL] [Abstract][Full Text] [Related]
6. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide.
Clift RA; Buckner CD; Thomas ED; Bensinger WI; Bowden R; Bryant E; Deeg HJ; Doney KC; Fisher LD; Hansen JA
Blood; 1994 Sep; 84(6):2036-43. PubMed ID: 8081005
[TBL] [Abstract][Full Text] [Related]
7. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.
Kröger N; Zabelina T; Krüger W; Renges H; Stute N; Kabisch H; Jaburg N; Löliger C; Krüll A; Zander AR
Bone Marrow Transplant; 2001 Feb; 27(4):349-54. PubMed ID: 11313663
[TBL] [Abstract][Full Text] [Related]
8. A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
Ringdén O; Labopin M; Tura S; Arcese W; Iriondo A; Zittoun R; Sierra J; Gorin NC
Br J Haematol; 1996 Jun; 93(3):637-45. PubMed ID: 8652385
[TBL] [Abstract][Full Text] [Related]
9. Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation.
Copelan EA; Avalos BR; Ahn KW; Zhu X; Gale RP; Grunwald MR; Hamadani M; Hamilton BK; Hale GA; Marks DI; Waller EK; Savani BN; Costa LJ; Ramanathan M; Cahn JY; Khoury HJ; Weisdorf DJ; Inamoto Y; Kamble RT; Schouten HC; Wirk B; Litzow MR; Aljurf MD; van Besien KW; Ustun C; Bolwell BJ; Bredeson CN; Fasan O; Ghosh N; Horowitz MM; Arora M; Szer J; Loren AW; Alyea EP; Cortes J; Maziarz RT; Kalaycio ME; Saber W
Biol Blood Marrow Transplant; 2015 Mar; 21(3):552-8. PubMed ID: 25528388
[TBL] [Abstract][Full Text] [Related]
10. Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination.
Carlens S; Ringdén O; Aschan J; Hägglund H; Ljungman P; Mattsson J; Remberger M
Clin Transplant; 1998 Apr; 12(2):84-92. PubMed ID: 9575394
[TBL] [Abstract][Full Text] [Related]
11. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
[TBL] [Abstract][Full Text] [Related]
12. Total body irradiation and cyclophosphamide plus antithymocyte globulin regimen is well tolerated and promotes stable engraftment as a preparative regimen before T cell-replete haploidentical transplantation for acute leukemia.
Fu H; Xu L; Liu D; Liu K; Zhang X; Chen H; Chen Y; Han W; Wang Y; Wang J; Wang F; Huang X
Biol Blood Marrow Transplant; 2014 Aug; 20(8):1176-82. PubMed ID: 24747336
[TBL] [Abstract][Full Text] [Related]
13. Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels.
Demirer T; Buckner CD; Appelbaum FR; Lambert K; Bensinger WI; Clift R; Storb R; Slattery JT
Bone Marrow Transplant; 1996 Mar; 17(3):341-6. PubMed ID: 8704684
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of patients after related- and unrelated-donor bone marrow transplantation for chronic myelogenous leukemia.
Reiter E; Greinix HT; Keil F; Brugger S; Rabitsch W; Schulenburg A; Mannhalter C; Schwarzinger I; Worel N; Volc-Platzer B; Fischer G; Dieckmann K; Hinterberger W; Schneider B; Haas OA; Geissler K; Kalhs P
Ann Hematol; 1999 Nov; 78(11):507-13. PubMed ID: 10602894
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Cyclophosphamide Combined with Total Body Irradiation, Oral Busulfan, or Intravenous Busulfan for Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Lymphoblastic Leukemia.
Mitsuhashi K; Kako S; Shigematsu A; Atsuta Y; Doki N; Fukuda T; Kanamori H; Onizuka M; Takahashi S; Ozawa Y; Kurokawa M; Inoue Y; Nagamura-Inoue T; Morishima Y; Mizuta S; Tanaka J;
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2194-2200. PubMed ID: 27638362
[TBL] [Abstract][Full Text] [Related]
16. Irradiation free conditioning regimen is associated with high relapse rate in Egyptian patients with acute lymphoblastic leukemia following allogeneic hematopoietic stem cell transplantation.
Abdelaty MM; Gawaly A; Fathy GM; Kabbash I; Taha A
J Egypt Natl Canc Inst; 2020 Jun; 32(1):28. PubMed ID: 32537680
[TBL] [Abstract][Full Text] [Related]
17. Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia.
Hirabayashi N; Goto S; Ishii M; Yuge M; Mitsuma A; Noda N
Bone Marrow Transplant; 1998 Jun; 21(11):1079-83. PubMed ID: 9645568
[TBL] [Abstract][Full Text] [Related]
18. Busulfan and cyclophosphamide versus cyclophosphamide and total body irradiation for marrow transplantation in chronic myelogenous leukemia--a review.
Santos GW
Leuk Lymphoma; 1993; 11 Suppl 1():201-4. PubMed ID: 8251896
[TBL] [Abstract][Full Text] [Related]
19. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
[TBL] [Abstract][Full Text] [Related]
20. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
Pichert G; Roy DC; Gonin R; Alyea EP; Bélanger R; Gyger M; Perreault C; Bonny Y; Lerra I; Murray C
J Clin Oncol; 1995 Jul; 13(7):1704-13. PubMed ID: 7602361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
